Huntington's disease is a devastating neurodegenerative disease caused by CAG codon expansion in exon 1 of the huntingtin (htt) gene. Similar CAG repeat expansions in eight other proteins are associated with eight different neurodegenerative diseases. In all nine diseases, the CAG repeat expansions encode polyglutamine expansions in the protein products, and the onset and severity of disease are inversely correlated with the polyglutamine length although the quantitative nature of this correlation is different for each of the nine disorders. Polyglutamine expansions end up in insoluble neuronal inclusions and there is growing evidence that the mechanisms of aggregation and the soluble oligomeric species are directly linked to selective neurodegeneration in each of the nine diseases. Polyglutamine expansions destabilize their host proteins and increase the likelihood of proteolysis. Fragments of proteolysis consist of polyglutamine tracts and flanking N- and C-terminal segments. The N- and C-terminal segments that flank the polyglutamine stretch are unique to each disease-related protein. Driving forces for aggregation of homopolymeric polyglutamine becomes stronger with increasing chain length and naturally occurring N- and C-terminal flanking sequences modulate this driving force. Our goal is to understand how sequences that flank polyglutamine expansions in disease-related proteins modulate the intrinsic, length-dependent conformational preferences and aggregation mechanisms of polyglutamine. Our approaches are based on a combination of novel atomistic simulations and a panel of in vitro experiments. Our recent results are consistent with the hypothesis that naturally occurring flanking sequences can act as """"""""gatekeepers"""""""" to suppress intrinsic aggregation propensities of aggregation-prone regions. Therefore, the current proposal is guided by the following hypothesis: Naturally occurring flanking sequences in disease-related proteins can act as gatekeepers to decrease the intrinsic aggregation tendencies of polyglutamine tracts. This effect can be overcome by expansion mutations that lead to increased polyglutamine lengths. Additionally, gatekeeping mechanisms likely vary with flanking sequence, giving rise to differences in gatekeeping efficiencies. We will use a combination of novel atomistic simulations and in vitro experiments to characterize 1) conformational changes within different naturally occurring terminal flanking sequences and the coupling between these changes and the degree of sequestration / exposure of aggregation-prone polyglutamine regions within intramolecular interfaces as a function of polyglutamine length and 2) if naturally occurring flanking sequences are bona fide gatekeepers and to quantify the degree to which these sequences modulate aggregation as a function of polyglutamine length. Precise understanding of the mechanisms of coupling between flanking sequences and polyglutamine expansions will allow us to identify targets for inhibition of routes to aggregation-mediated toxicity and neurodegeneration.

Public Health Relevance

There is clear connection between aggregation and the onset of devastating polyglutamine expansion diseases such as Huntington's disease. The role of flanking sequences in modulating aggregation is of direct relevance to the progression of polyglutamine expansion diseases. Mechanistic studies proposed here have a direct bearing on the development of drugs that inhibit the gain of function associated with polyglutamine aggregation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS056114-06
Application #
8286799
Study Section
Special Emphasis Panel (ZRG1-MDCN-E (03))
Program Officer
Sutherland, Margaret L
Project Start
2007-04-15
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
6
Fiscal Year
2012
Total Cost
$332,500
Indirect Cost
$113,750
Name
Washington University
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Franzmann, Titus M; Jahnel, Marcus; Pozniakovsky, Andrei et al. (2018) Phase separation of a yeast prion protein promotes cellular fitness. Science 359:
Newcombe, Estella A; Ruff, Kiersten M; Sethi, Ashish et al. (2018) Tadpole-like Conformations of Huntingtin Exon 1 Are Characterized by Conformational Heterogeneity that Persists regardless of Polyglutamine Length. J Mol Biol 430:1442-1458
Fuertes, Gustavo; Banterle, Niccolo; Ruff, Kiersten M et al. (2018) Comment on ""Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in water"". Science 361:
Wang, Jie; Choi, Jeong-Mo; Holehouse, Alex S et al. (2018) A Molecular Grammar Governing the Driving Forces for Phase Separation of Prion-like RNA Binding Proteins. Cell 174:688-699.e16
Staller, Max V; Holehouse, Alex S; Swain-Lenz, Devjanee et al. (2018) A High-Throughput Mutational Scan of an Intrinsically Disordered Acidic Transcriptional Activation Domain. Cell Syst 6:444-455.e6
Posey, Ammon E; Ruff, Kiersten M; Harmon, Tyler S et al. (2018) Profilin reduces aggregation and phase separation of huntingtin N-terminal fragments by preferentially binding to soluble monomers and oligomers. J Biol Chem 293:3734-3746
Holehouse, Alex S; Pappu, Rohit V (2018) Collapse Transitions of Proteins and the Interplay Among Backbone, Sidechain, and Solvent Interactions. Annu Rev Biophys :
Holehouse, Alex S; Pappu, Rohit V (2018) Functional Implications of Intracellular Phase Transitions. Biochemistry 57:2415-2423
Best, Robert B; Zheng, Wenwei; Borgia, Alessandro et al. (2018) Comment on ""Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in water"". Science 361:
Garai, Kanchan; Posey, Ammon E; Li, Xinyi et al. (2018) Inhibition of amyloid beta fibril formation by monomeric human transthyretin. Protein Sci 27:1252-1261

Showing the most recent 10 out of 40 publications